Skip to content

High-dose vs. standard-dose caffeine therapy for apnea of prematurity.

High-dose vs. standard dose caffeine therapy for apnea of prematurity: a randomised control trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202604505368563
Enrollment
122
Registered
2026-04-24
Start date
2025-10-21
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paediatrics

Interventions

Sponsors

Kyambadde Ronald
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Preterm babies with gestational age = 34 weeks by the New Ballard Score. 2. Preterm babies admitted to the Newborn unit at St. Francis Hospital Nsambya and Uganda Martyrs Hospital, Lubaga during the study period.

Exclusion criteria

Exclusion criteria: 1. Presence of congenital diaphragmatic hernia or Lung hypoplasia diagnosed prenatally. 2. Participants with a New Ballard score >34 weeks at admission.

Design outcomes

Primary

MeasureTime frame
Frequency and severity of apnea episodes. Apnea episodes were documented using standard criteria of the cessation of breathing for more than 20 seconds or the cessation of breathing for less than 20 seconds if it is accompanied by bradycardia (less than 100 beats per minute) or oxygen desaturation (less than 90 %).

Secondary

MeasureTime frame
Adverse events related to caffeine therapy at different dosages

Countries

Uganda

Contacts

Public ContactKyambadde Ronald

medical doctor

kyldas93@gmail.com+256771931295

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Jun 29, 2026